A comparison of results
Protein array
without LowCross-Buffer® with LowCross-Buffer®
(data from Dipl. Chem. N. Dankbar, University of Münster)
without LowCross-Buffer® with LowCross-Buffer®
(data from Dipl. Chem. N. Dankbar, University of Münster)
reduction of background
multiple antibodies against an identical analyte spotted on a slide
signal to noise ratio
without LowCross-Buffer®: 3,42
with LowCross-Buffer®: 17,26
multiple antibodies against an identical analyte spotted on a slide
signal to noise ratio
without LowCross-Buffer®: 3,42
with LowCross-Buffer®: 17,26
ELISA
(data from Dr. C. Specht, PARA Bioscience GmbH, Gronau)
(data from Dr. C. Specht, PARA Bioscience GmbH, Gronau)
Avoid false-positive binding
control of specifity in (A1-12) and blanks (H1-H12) show false positive binding.
control of specifity in (A1-12) and blanks (H1-H12) show false positive binding.
HAMA-ELISA
Active against HAMA and Rheumatoid Factor
Fig.1: HAMA Serum
Fig.2: RF Serum
Fig.3: HAMA Sera
Fig.3 shows LowCross-Buffer® effect on HAMAs using complete commercial HAMA positive human blood sera panels from the companies in.vent diagnostica, Germany and Scantibodies, USA.
Only data from sera tested positive with HAMA-ELISA are shown.
There was no HAMA-positive serum, which did not show this effect by using LowCross-Buffer®. LowCross-Buffer® reduces interferences in HAMA positive samples to background levels (<40 ng/ml, according to HAMA-ELISA manual).
Active against HAMA and Rheumatoid Factor
Fig.1: HAMA Serum
Fig.2: RF Serum
Fig.3: HAMA Sera
Fig.3 shows LowCross-Buffer® effect on HAMAs using complete commercial HAMA positive human blood sera panels from the companies in.vent diagnostica, Germany and Scantibodies, USA.
Only data from sera tested positive with HAMA-ELISA are shown.
There was no HAMA-positive serum, which did not show this effect by using LowCross-Buffer®. LowCross-Buffer® reduces interferences in HAMA positive samples to background levels (<40 ng/ml, according to HAMA-ELISA manual).
The
effectiveness of LowCross-Buffer® towards HAMA and RF derived
interferences has been quantified in a CE-certified ELISA (HAMA-ELISA,
Medac, Germany) using commercial HAMA and RF positive human blod samples
(in.vent diagnostica, Germany). Representative results obtained with
and without LowCross-Buffer® are shown in fig. 1 and fig. 2.
ELISA
(data from Dr. P. Rauch, CANDOR Bioscience GmbH)
(data from Dr. P. Rauch, CANDOR Bioscience GmbH)
Decrease CV
Interference from used human plasma caused a high coefficient of variation (CV) with PBS/BSA Tween (n=96, determined over the whole measurement range).
CV is decreased significantly by using LowCross-Buffer®.
The reason is the avoidance of an interference effect. Thus criteria of the "Guidance for Industry - Bioanalytical Method Validation" of the FDA could be met. They require for accuracy and precision a maximum of 15%.
Interference from used human plasma caused a high coefficient of variation (CV) with PBS/BSA Tween (n=96, determined over the whole measurement range).
CV is decreased significantly by using LowCross-Buffer®.
The reason is the avoidance of an interference effect. Thus criteria of the "Guidance for Industry - Bioanalytical Method Validation" of the FDA could be met. They require for accuracy and precision a maximum of 15%.
ELISA
without LowCross-Buffer® with LowCross-Buffer®
(data from Dr. Ch. Specht, PARA BioScience GmbH, Gronau)
without LowCross-Buffer® with LowCross-Buffer®
(data from Dr. Ch. Specht, PARA BioScience GmbH, Gronau)
better sensitivity,
(LOD lowered from 0,051 to 0,022 and LOQ from 0,152 to 0,065, in addition to an improved working range), elimination of cross reactivities in preimmunsera, reduction of background
antigen coated, serial dilutions of four immunsera (1:50 to 1:36450) A-G, corresponding preimmunsera in H blank value: column 5
(LOD lowered from 0,051 to 0,022 and LOQ from 0,152 to 0,065, in addition to an improved working range), elimination of cross reactivities in preimmunsera, reduction of background
antigen coated, serial dilutions of four immunsera (1:50 to 1:36450) A-G, corresponding preimmunsera in H blank value: column 5
ELISA
(data from M. Braun, PD Dr. H.-P. Wendel, Clinic of Thorax-, Cardiac- and Vascular Surgery, research laboratory, University Hospital of Tübingen)
(data from M. Braun, PD Dr. H.-P. Wendel, Clinic of Thorax-, Cardiac- and Vascular Surgery, research laboratory, University Hospital of Tübingen)
reduction of background
reporter antibody is coupled to alkaline phosphatase. It binds nonspecifically and directly to the capture antibody in absence of the analyte.
LowCross-Buffer® prevents this non-specific binding. Background of the assay is significantly reduced.
reporter antibody is coupled to alkaline phosphatase. It binds nonspecifically and directly to the capture antibody in absence of the analyte.
LowCross-Buffer® prevents this non-specific binding. Background of the assay is significantly reduced.
ELISA
(data from A. Zellmer, Dr. P. Rauch, CANDOR Bioscience GmbH)
(data from A. Zellmer, Dr. P. Rauch, CANDOR Bioscience GmbH)
eliminate matrix effect
Matrix effect in an assay for detection of CRP (c-reactive protein) in rabbit blood plasma. Matrix proteins in plasma mask the analyte CRP.
LowCross-Buffer® demasks the analyte and improves sensitivity and detection limit by a factor of 3.
Matrix effect in an assay for detection of CRP (c-reactive protein) in rabbit blood plasma. Matrix proteins in plasma mask the analyte CRP.
LowCross-Buffer® demasks the analyte and improves sensitivity and detection limit by a factor of 3.
Western blotting
(data from Dr. D. Sperling, MACHEREY-NAGEL, Düren)
(data from Dr. D. Sperling, MACHEREY-NAGEL, Düren)
avoid nonspecific binding
detection of cytokeratin 4, 5 and 6 is affected by a combination of nonspecific binding and cross-ractivities in a dramatic way. The exspected bands can be clearly detected with LowCross-Buffer®.
Lanes 1 and 1' show detection from liver cells
Lanes 2 and 2' show detection from HeLa-cells
detection of cytokeratin 4, 5 and 6 is affected by a combination of nonspecific binding and cross-ractivities in a dramatic way. The exspected bands can be clearly detected with LowCross-Buffer®.
Lanes 1 and 1' show detection from liver cells
Lanes 2 and 2' show detection from HeLa-cells
Immuno-PCR
1 2 3 4 5 6 7 1 2 3 4 5 6 7
(data from A. Fischer, PD Dr. K. Becker, Institute of Medical Microbiology, University Hospital of Münster)
1 2 3 4 5 6 7 1 2 3 4 5 6 7
(data from A. Fischer, PD Dr. K. Becker, Institute of Medical Microbiology, University Hospital of Münster)
reduction of nonspecific binding (lane 5-7)
detection of Enterotoxin A from staphylococcus
nonspecific binding, producing false-positive results, is completely reduced by use of LowCross-Buffer®
detection of Enterotoxin A from staphylococcus
nonspecific binding, producing false-positive results, is completely reduced by use of LowCross-Buffer®
more